Recent News for ARVN - Arvinas, Inc.

Date Title
Nov 27 Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference
Nov 26 The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug
Nov 25 Arvinas TPD Therapies Have Great Potential, Guggenheim Says In Bullish Initiation
Nov 25 Benzinga's Top Upgrades, Downgrades For November 25, 2019
Nov 22 The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
Nov 21 Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors
Nov 20 The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
Nov 17 Notable Insider Buys In The Past Week: Arvinas, Dropbox, Trinity
Nov 14 JPMorgan likes Qiagen in premarket analyst action
Nov 7 Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
Nov 6 Arvinas, Inc. Announces Proposed Offering of Common Stock
Nov 5 Arvinas, Inc. (ARVN) Upgraded to Strong Buy: Here's Why
Nov 4 Arvinas EPS misses by $0.07, beats on revenue
Nov 4 Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Oct 31 Goldman Sachs: 3 Standout Healthcare Stocks That Could Double
Oct 30 Hedge Funds Are Selling Arvinas, Inc. (ARVN)
Oct 29 Arvinas: Initial Clinical Data Provides Validation For PROTAC Platform
Oct 23 PDL BioPharma leads healthcare gainers; OPKO Health and CHF Solutions among losers
Oct 23 Arvinas up 13% on encouraging cancer candidate data
Oct 23 The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data
Oct 23 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTACĀ® Targeted Protein Degraders
Oct 20 The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
Oct 19 Stocks To Watch: Blue Chips Join The Earnings Parade
Oct 19 Have Insiders Been Buying Arvinas, Inc. (NASDAQ:ARVN) Shares This Year?
Oct 17 Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit

Back to the Main ARVN Page...